The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

Table 5

Salvage therapy in relapsing/refractory DLBCLs previously exposed to rituximab.

Author	Year	Kind of study	𝑛	Pathological phenotype	DLCL (%)	Therapy	Conditioning regimen	PFS/EFS (%)	𝑃	OS (%)	𝑃
Martín [40]	2008	Retrospective	94; 69	WHO	100	R-ESHAP (prior R) R-ESHAP (no prior R)	*	3y: 17; 3y: 57	0.008	3y: 38; 3y: 67	0.004
Fenske [41]	2009	Retrospective	818; 176	WHO	100	R-CT (no prior R) R-CT (prior R)	*	3y: 50; 3y: 38	0.008	3y: 57; 3y: 45	0.006
Gisselbrecht [42]	2010	Perspective	194; 202	WHO	100	R-DHAP R-ICE	BEAM	3y: 42; 3y: 31	N.S.	2y: 51; 2y: 47	N.S.

*The choice of conditioning regimen depended on the patient’s age, the extent of previous therapy, and the clinical trials active at the time of transplantation (see [40, 41]).
WHO: World Health Organization classification of NHL; R: rituximab; ESHAP: etoposide, methylprednisolone, cisplatin, and cytarabine; CT: multiple variable regimes; ICE: ifosfamide, carboplatin, and etoposide; DHAP: cisplatin, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine, and melphalan; N.S.: not significant.